Enrolment completion for CB03-154 leaves a pivotal Phase II/III readout without any efficacy to underwrite the conditional filing plan, making this a mechanism-testing event rather than a de-risking one. The trial recruited 255 patients across 15 centers in mainland China with change in ALSFRS-R at week 39 as primary endpoint, targeting a China CDE conditional filing in third quarter of 2027 pending positive Phase II top-line data after US FDA orphan designation in October 2023. Competitive context is crowded and mechanistically distinct: tofersen in SOD1 ALS supported by VALOR Phase 3 RCT with 28-week ALSFRS-R primary and NfL reductions enabling accelerated approval, and sodium phenylbutyrate-taurursodiol supported by CENTAUR randomized Phase 2 plus PHOENIX Phase 3 with later withdrawal, alongside riluzole and edaravone as globally approved therapies with modest survival benefits. [1][2] Payer pressure is material, with AMX0035 at $158,000 annually cited as a financial barrier and German ALS costs at 83,060 euros annually with 138,960 euros per QALY. [3] Regulatory principles require muscle-strength or respiratory effects to be supported by magnitude of change or function in activities of daily living, with mortality integrated via joint rank test. [4] No closely comparable precedent exists sharing both potassium-opener mechanism and ALS ALSFRS-R context, so success rests entirely on undisclosed week-39 data and biomarker-free conditional acceptance.
Pivotal Phase II/III completed 255-patient enrolment with week-39 ALSFRS-R primary but disclosed no efficacy, safety or NfL data to judge conditional filing.
| Indication | Amyotrophic Lateral Sclerosis |
| Drug | CB03-154 |
| Mechanism of Action | potassium-channel opener |
| Company | Zhimeng Biopharma |
| Trial Phase | Phase II/III |
| Category | Clinical Trial Event |
| Sub Category | Patient Enrollment Milestone |
| Therapeutic Area | Neuroscience |
| Patient Population Size | 255 |
| Clinical Research Centers | 15 |
| Principal Investigator | Professor Fan Dongsheng |
| Primary Efficacy Endpoint | Change from baseline in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at week 39 |
| CDE Trial Initiation Approval Date | July 2025 |
| FDA Orphan Drug Designation Date | October 2023 |
| Expected Phase II Top-line Data | Third quarter of 2027 |
| Conditional Approval Target Region | China |
| Additional Indication | Focal epilepsy |
| Additional Indication Trial Regions | Australia, China |
Zhimeng Biopharma Completes Patient Enrollment for ALS Trial
Shanghai Zhimeng Biopharma has successfully completed patient enrolment for its pivotal Phase II/III clinical trial of CB03-154, an investigational potassium-channel opener, for amyotrophic lateral sclerosis (ALS). The trial recruited 255 patients across 15 clinical research centers in mainland China. The primary efficacy endpoint is the change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at week 39. The company aims to file a marketing application for conditional approval with the China CDE in the third quarter of 2027, pending positive Phase II top-line data. CB03-154 previously received orphan drug designation from the US FDA in October 2023.
- Zhimeng Biopharma has finalized patient recruitment for its Phase II/III ALS trial of CB03-154, enrolling 255 patients across 15 clinical research centers in mainland China. This significant milestone, overseen by Principal Investigator Professor Fan Dongsheng, marks a crucial step towards potentially bringing a new treatment option to ALS patients. The completion of enrolment sets the stage for data collection and analysis in this pivotal study.
- CB03-154, an independently discovered potassium-channel opener, demonstrated neuroprotective effects on motor neurons in preclinical studies by modulating neuronal excitability, restoring the balance between excitation and inhibition. The trial's primary efficacy endpoint is defined as the change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at week 39, a standard measure for assessing functional decline in ALS patients.
- The China Centre for Drug Evaluation (CDE) approved the initiation of this Phase II/III ALS trial in July 2025, following the US FDA's orphan drug designation for CB03-154 in October 2023. Zhimeng Biopharma plans to seek conditional approval from the China CDE in Q3 2027, contingent on positive Phase II top-line data, reflecting a patient-centered approach to accelerate access to innovative treatments for rare diseases.
- Beyond ALS, CB03-154 is also being developed for other central nervous system (CNS) indications. As of October 2026, the drug had advanced into Phase II trials for focal epilepsy in both Australia and China, indicating the company's broader strategy to leverage the drug's mechanism across multiple neurological conditions.
Navigating the Challenges of Current ALS Treatment
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease with limited treatment options. Single-target therapies often show limited efficacy due to the complex, interconnected nature of disease pathways, and recent randomized trials have not slowed functional decline.
Single-target approaches against network pathology: Core contributors include oxidative stress, mitochondrial dysfunction, protein aggregation, neuroinflammation, and emerging roles of peroxisomal dysfunction in redox imbalance, lipid dysregulation, and inflammatory amplification. Polypharmacology, which targets multiple disease-relevant mechanisms simultaneously, offers a more promising therapeutic strategy.
Lack of direct comparisons and inconsistent endpoints: Currently, there are no head-to-head studies to compare the efficacy of riluzole, edaravone, sodium phenylbutyrate and taurursodiol (SPT) and tofersen. The difference in outcome measures limits important comparison between interventions, and non-significant findings may preclude any strong recommendation for its use.
Patient heterogeneity and stratification failure: The heterogeneity of patient population limits the interpretability of our results. The ALSFRS-R change in the run-in period or from onset to baseline is not useful for stratifying subsequent progression of functional decline.
Translational barriers to CNS delivery and monitoring: Successful translation into clinical practice remains constrained by challenges such as blood-brain barrier penetration, patient heterogeneity, and biomarker limitations.
Safety, tolerability and adherence constraints: The most common reasons for dose modification were related to adverse effects, yet social-, economic-, and patient-related factors were also common. Dropouts and serious adverse events occurred more frequently in the tirasemtiv group, while terminal complement C5 inhibition with ravulizumab did not slow functional decline and FMT did not significantly slow the decline in ALSFRS-R score.
Unpacking the Pivotal Phase II/III Trial of CB03-154 in ALS
Recent ALS trials span early pilot to phase 2/3 platform designs, testing diverse mechanisms against functional decline and survival. Primary endpoints center on ALSFRS-R change or slope, combined function-survival models, and self-sufficiency, with respiratory function, strength, and biomarkers as key secondaries.
| Trial / Intervention | Design & Population | Treatment Arms & Duration | Primary Endpoint(s) | Secondary / Other Endpoints |
|---|---|---|---|---|
| FORTITUDE-ALS, reldesemtiv (NCT03160898) | Post hoc analysis of clinical trial, 456 participants in full-analysis set | Reldesemtiv or placebo for 12 weeks | Relationship among strength, function, and quality of life | Slow vital capacity (SVC), ALS Functional Rating Scale-Revised (ALSFRS-R), 5-item ALS Assessment Questionnaire (ALSAQ-5), muscle strength by hand-held dynamometry and grip strength |
| TUDCA-ALS, tauroursodeoxycholic acid as add-on to riluzole (NCT03800524) | Double-blinded, parallel arms, placebo-controlled, randomized multicenter phase III trial | TUDCA vs placebo as add-on therapy to riluzole; lead-in period (3 months) and randomized treatment period (18 months); randomization stratified by country | Treatment response defined as a minimum of 20% improvement in the ALS Functional Rating Scale-Revised (ALSFRS-R) slope during the randomized treatment period (18 months) compared to the lead-in period (3 months) | Sensitivity analyses to assess impact of intercurrent events related to coronavirus disease 2019; primary analysis via unadjusted logistic regression model on intention-to-treat principle |
| GALS-001, GM604 | 2-center phase 2A, randomized, double-blind, placebo-controlled pilot trial with 12 definite ALS patients diagnosed within 2 years of disease onset | GM604, n = 8 vs placebo, n = 4; 6 doses administered as slow IV bolus injections (3x/week, 2 consecutive weeks) | Safety and efficacy based on ALSFRS-R, FVC and selected biomarkers (TDP-43, Tau and SOD1, pNFH) | Change in respiratory function (FVC) between baseline and week 12; plasma levels of TDP-43, Tau, SOD1 |
| HEALEY ALS Platform Trial, CNM-Au8 (NCT04297683, NCT04414345) | Phase 2/3, multicenter, randomized, double-blind platform trial at 54 sites in the US from July 2020 to March 2022; 161 participants randomized | CNM-Au8 60 mg daily (n = 61), CNM-Au8 30 mg daily (n = 59), or matching placebo (n = 41) for 24 weeks; 3:3:2 randomization | Change from baseline through week 24 in ALS disease severity measured by a bayesian shared parameter model of function (based on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale) and survival, providing disease rate ratio (DRR) | Combined Assessment of Function and Survival using joint-rank test, rate of decline in slow vital capacity (percent predicted), and survival free of permanent assisted ventilation |
| ROPALS, ropinirole hydrochloride extended-release tablet (UMIN000034954 and JMA-IIA00397) | Single-center double-blind randomized parallel group-controlled phase I/IIa trial; 20 patients with El Escorial Possible, clinically possible and laboratory-supported, clinically probable, or clinically definite ALS with disease duration less than 60 months | Active drug group (fifteen patients) vs placebo group (five patients); ropinirole hydrochloride 2- to 16-mg doses; riluzole allowed if dosage unchanged | Safety and tolerability at 24 weeks, defined from date of randomization | Change in ALS Functional Rating Scale-Revised (ALSFRS-R), change in Combined Assessment of Function and Survival (CAFS), and composite endpoint as sum of Z-transformed scores on various clinical items |
| Tetramethylpyrazine nitrone (ChiCTR2000039689) | Phase 2, multicenter, double-masked, placebo-controlled, randomized trial in 11 centers in China from December 24, 2020, through July 14, 2023, with 180-day follow-up; 155 patients aged 45 to 70 years with ALS onset within 2 years | Low-dose tetramethylpyrazine nitrone (600 mg twice daily, n = 51), high-dose (1200 mg twice daily, n = 52), or placebo (twice daily, n = 52) for 180 days | Change in ALSFRS-R score (range 0-48) from baseline to 180 days | Changes in FVC, grip strength, ALS Assessment Questionnaire-40 (ALSAQ-40) score, and end point events; safety outcomes including adverse events |
| TJ-68 for muscle cramps | Double-blind, randomized, placebo-controlled crossover N-of-1 pilot trial, consisting of four periods, at three centers in the USA; 11 participants enrolled | TJ-68 vs placebo crossover | Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity (item #5 of the Muscle Cramp Scale) | Remaining items of the Muscle Cramp Scale and Clinical Global Impression of Changes (CGIC), among others; safety evaluated using multiple measures |
| Acetyl-L-carnitine (ALC) with riluzole | Pilot double-blind, placebo-controlled, parallel group trial; definite/probable ALS patients 40-70 years, duration 6-24 months, self-sufficient with forced vital capacity > 80%; followed for 48 weeks | ALC 3 g/day (n = 42) or placebo (n = 40) added to riluzole 100 mg/day | Number of patients no longer self-sufficient | Changes in ALSFRS-R, MRC, FVC and McGill Quality of Life scores; median survival |
| Creatine 5 to 10 g per day vs placebo | Systematic review of randomized trials; three trials involving 386 participants randomized to creatine or placebo | Creatine 5 to 10 g per day or placebo | Tracheostomy-free survival time | ALS progression as measured by changes in ALS functional rating revised scores (ALSFRS-R) and percent predicted forced vital capacity (FVC) over time |
Frequently Asked Questions
References
- [1] Koch JC, Leha A et al.. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2024 Nov. 39424560
- [2] Jung HJ, Jeong WS et al.. Serum GFAP predicts survival in advanced ALS: a prospective multicenter study. Journal of neurology. 2025 Jul 24. 40705135
- [3] Roca-Pereira S, López-Sampere Y et al.. Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival. Brain pathology (Zurich, Switzerland). 2026 Sep. 41776751
- [4] Kataoka H, Kiriyama T et al.. Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged ≥ 70 years. American journal of neurodegenerative disease. 2013. 23844338
- [5] Hassan M, Sehgal SA et al.. Regulatory cascade of neuronal loss and glucose metabolism. CNS & neurological disorders drug targets. 2014. 25230224
- [6] Genge A, van den Berg LH et al.. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA neurology. 2023 Oct 1. 37695623
- [7] Hamatani T, Atsuta N et al.. ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2024 May. 38323575
- [8] Mitsumoto H, Cheung K et al.. Placebo-Controlled, Randomized Double-Blind N-Of-1 Trial to Study Safety and Potential Efficacy of TJ-68 for Improving Muscle Cramps in Patients With Amyotrophic Lateral Sclerosis: A Pilot Study. Muscle & nerve. 2025 Sep. 40545904
- [9] Pastula DM, Moore DH et al.. Creatine for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane database of systematic reviews. 2010 Jun 16. 20556761
- [10] Depp C, Bas-Orth C et al.. Synaptic Activity Protects Neurons Against Calcium-Mediated Oxidation and Contraction of Mitochondria During Excitotoxicity. Antioxidants & redox signaling. 2018 Oct 20. 28990420
- [11] Shefner JM, Wolff AA et al.. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2016 Jul-Aug. 26982815
- [12] Khan MS, Zafar I et al.. Polypharmacology of Pathway Crosstalk in Neurodegenerative Diseases: Chemical Modulation of Interconnected Signaling Networks. Cells. 2026 May 22. 42274555
- [13] Berry JD, Maragakis NJ et al.. CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA. 2025 Feb 17. 40067821
- [14] Liu X, Shang H et al.. Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA network open. 2025 Feb 3. 39992655
- [15] Meyer T, Schumann P et al.. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice. Muscle & nerve. 2023 Jun. 36928619
- [16] Weemering DN, Midei M et al.. A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis. European journal of neurology. 2023 Dec. 37550954
- [17] Alqallaf A, Cates DW et al.. Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. The Annals of pharmacotherapy. 2024 Feb. 37269231
- [18] Timmins HC, Thompson AE et al.. Diagnostic criteria for amyotrophic lateral sclerosis. Current opinion in neurology. 2024 Oct 1. 39037015
- [19] Pastula DM, Moore DH et al.. Creatine for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane database of systematic reviews. 2012 Dec 12. 23235621
- [20] Heffernan ÁB, Do F et al.. Disrupted astrocyte-neuron metabolic coupling in amyotrophic lateral sclerosis. Frontiers in cell and developmental biology. 2026. 42694267
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
